An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2

Tomer Meirson, Abraham O Samson, Hava Gil-Henn Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel Abstract: The non-receptor tyrosine kinase proline-rich tyrosine kinase 2 (Pyk2) is a critical mediator of signaling from cell surface growth factor and adhesion receptors to cell mi...

Full description

Saved in:
Bibliographic Details
Main Authors: Meirson T (Author), Samson AO (Author), Gil-Henn H (Author)
Format: Book
Published: Dove Medical Press, 2017-05-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_01ef532f9e614f8e825e52cbe2a3c24b
042 |a dc 
100 1 0 |a Meirson T  |e author 
700 1 0 |a Samson AO  |e author 
700 1 0 |a Gil-Henn H  |e author 
245 0 0 |a An in silico high-throughput screen identifies potential selective inhibitors for the non-receptor tyrosine kinase Pyk2 
260 |b Dove Medical Press,   |c 2017-05-01T00:00:00Z. 
500 |a 1177-8881 
520 |a Tomer Meirson, Abraham O Samson, Hava Gil-Henn Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, Israel Abstract: The non-receptor tyrosine kinase proline-rich tyrosine kinase 2 (Pyk2) is a critical mediator of signaling from cell surface growth factor and adhesion receptors to cell migration, proliferation, and survival. Emerging evidence indicates that signaling by Pyk2 regulates hematopoietic cell response, bone density, neuronal degeneration, angiogenesis, and cancer. These physiological and pathological roles of Pyk2 warrant it as a valuable therapeutic target for invasive cancers, osteoporosis, Alzheimer’s disease, and inflammatory cellular response. Despite its potential as a therapeutic target, no potent and selective inhibitor of Pyk2 is available at present. As a first step toward discovering specific potential inhibitors of Pyk2, we used an in silico high-throughput screening approach. A virtual library of six million lead-like compounds was docked against four different high-resolution Pyk2 kinase domain crystal structures and further selected for predicted potency and ligand efficiency. Ligand selectivity for Pyk2 over focal adhesion kinase (FAK) was evaluated by comparative docking of ligands and measurement of binding free energy so as to obtain 40 potential candidates. Finally, the structural flexibility of a subset of the docking complexes was evaluated by molecular dynamics simulation, followed by intermolecular interaction analysis. These compounds may be considered as promising leads for further development of highly selective Pyk2 inhibitors. Keywords: virtual screen, efficiency metrics, MM-GBSA, molecular dynamics 
546 |a EN 
690 |a Pyk2 
690 |a virtual screen 
690 |a efficiency metrics 
690 |a molecular dynamics 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Drug Design, Development and Therapy, Vol Volume 11, Pp 1535-1557 (2017) 
787 0 |n https://www.dovepress.com/an-in-silico-high-throughput-screen-identifies-potential-selective-inh-peer-reviewed-article-DDDT 
787 0 |n https://doaj.org/toc/1177-8881 
856 4 1 |u https://doaj.org/article/01ef532f9e614f8e825e52cbe2a3c24b  |z Connect to this object online.